Andreas H. Diacon

Cape Town, Western Cape
Cape Town, WC, South Africa

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 196 publications

Activity of a three-phage combination against Mycobacterium tuberculosis in disease-relevant conditions.

Activity of a three-phage combination against Mycobacterium tuberculosis in disease-relevant conditions.

Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026

Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine.

Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine.

Journal: The Journal of infectious diseases
Published: April 30, 2026

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.

Exposure-QTc modeling of bedaquiline, pretomanid, and clofazimine in adults with tuberculosis.

Journal: Antimicrobial agents and chemotherapy
Published: March 09, 2026

Revival of Ethionamide by Alpibectir.

Revival of Ethionamide by Alpibectir.

Journal: The New England journal of medicine
Published: February 18, 2026

Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB.

Effect of HIV on bedaquiline and delamanid pharmacokinetics in patients with multidrug-resistant TB.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Published: February 10, 2026

Bacteriophage inactivation to prevent carry-over in preclinical assays with mycobacteria.

Bacteriophage inactivation to prevent carry-over in preclinical assays with mycobacteria.

Journal: Research square
Published: February 06, 2026

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials.

Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials.

Journal: CPT: pharmacometrics & systems pharmacology
Published: January 16, 2026

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

Clinical testing of drug treatment shortening in patients with TB using PET/CT imaging of lung lesions.

Journal: Science translational medicine
Published: January 07, 2026

Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.

Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.

Journal: Antimicrobial agents and chemotherapy
Published: October 21, 2025

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.

Journal: The Lancet. Infectious diseases
Published: September 11, 2025

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.

Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis.

Journal: Nature communications
Published: May 13, 2025

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.

Journal: Nature communications
Published: April 09, 2025
Showing 1-12 of 196

Last Updated: 09/26/2026